BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30630516)

  • 1. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.
    Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J
    Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.
    Bhatia A; Hatzoglou V; Ulaner G; Rampal R; Hyman DM; Abdel-Wahab O; Durham BH; Dogan A; Ozkaya N; Yabe M; Petrova-Drus K; Panageas KS; Reiner A; Rosenblum M; Diamond EL
    Neuro Oncol; 2020 Jul; 22(7):979-992. PubMed ID: 31950179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Young JR; Johnson GB; Murphy RC; Go RS; Broski SM
    J Nucl Med; 2018 May; 59(5):774-779. PubMed ID: 29097410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
    Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
    Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease.
    Arnaud L; Malek Z; Archambaud F; Kas A; Toledano D; Drier A; Zeitoun D; Cluzel P; Grenier PA; Chiras J; Piette JC; Amoura Z; Haroche J
    Arthritis Rheum; 2009 Oct; 60(10):3128-38. PubMed ID: 19790052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
    Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
    [No Abstract]   [Full Text] [Related]  

  • 10. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
    Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
    Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal involvement in Erdheim-Chester disease: Multimodality imaging features and association with the BRAF
    Nikpanah M; Dehghani Firouzabadi F; Farhadi F; Mirmomen SM; Ahlman MA; Huda F; Millo C; Saboury B; Paschall AK; Gahl WA; Estrada-Veras JI; Turkbey E; Jones EC; O'Brien K; Malayeri AA
    Clin Imaging; 2024 Feb; 106():110067. PubMed ID: 38128404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
    Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Usefulness of combined positron emission tomography and computed tomography imaging in Erdheim-Chester disease].
    Girszyn N; Arnaud L; Villain D; Kahn JE; Piette AM; Bletry O
    Rev Med Interne; 2007 Nov; 28(11):770-4. PubMed ID: 17629593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature].
    Adam Z; Petrášová H; Řehák Z; Koukalová R; Krejčí M; Pour L; Vetešníková E; Čermák A; Ševčíková S; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2016; 62(10):820-832. PubMed ID: 27900869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
    Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
    Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
    Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
    Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 2-[
    Pudis M; Palomar-Muñoz A; Solanich-Moreno X; Robles-Barba JJ; Rocamora-Blanch G; Rodríguez-Bel L; Narváez JA; Cortés-Romera M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(1):14-22. PubMed ID: 37804884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.